We promote the understanding of assessment and access processes for life science products to support the development and adoption of innovative treatments
Spain plans to advance a new medicines and medical devices law in 2026, keeping proposed reforms to reference pricing, early access, public-financing criteria and pharmacy substitution on the Government’s legislative agenda.
The national health service in Greece has formalised its annual expenditure ceilings for medical products and services alongside the first monthly clawback data for the current year.
